menu
    • menu
    [{"orgOrder":0,"company":"Moksha8 Pharmaceuticals","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Methylphenidate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Moksha8 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Moksha8 Pharmaceuticals \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"12","companyTruncated":"Moksha8 Pharmaceuticals \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Neos Therapeutics","sponsor":"Aytu BioScience","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Merger","leadProduct":"Methylphenidate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Neos Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Neos Therapeutics \/ Aytu BioScience","highestDevelopmentStatusID":"12","companyTruncated":"Neos Therapeutics \/ Aytu BioScience"},{"orgOrder":0,"company":"KemPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Methylphenidate","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Phase I","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"KemPharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"KemPharm \/ Not Applicable"},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Methylphenidate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aytu BioPharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating, Extended Release","sponsorNew":"Aytu BioPharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aytu BioPharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Methylphenidate

    Menu

    Methylphenidate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Aytu BioPharma

    U.S.A arrow
    ELCC
    Not Confirmed

    Aytu BioPharma

    U.S.A arrow
    ELCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Methylphenidate

    Therapeutic Area : Psychiatry/Psychology

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplem...

    Details : Cotempla XR-ODT (methylphenidate extended-release orally disintegrating tablets) is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age.

    Product Name : Cotempla

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    October 26, 2023

    Lead Product(s) : Methylphenidate

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    KemPharm

    U.S.A arrow
    ELCC
    Not Confirmed

    KemPharm

    U.S.A arrow
    ELCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Methylphenidate

    Therapeutic Area : Sleep

    Study Phase : Phase I

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    KemPharm Doses First Subject in Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenida...

    Details : Prodrug of d-methylphenidate, is sole API in KP1077, a potential first-ever therapeutic treatment for Idiopathic Hypersomnia, a neurological disorder marked by significant, detrimental effects on nighttime sleep as well as daytime sleepiness/wakefulness.

    Product Name : KP1077

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    April 19, 2022

    Lead Product(s) : Methylphenidate

    Therapeutic Area : Sleep

    Highest Development Status : Phase I

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Neos Therapeutics

    U.S.A arrow
    ELCC
    Not Confirmed

    Neos Therapeutics

    U.S.A arrow
    ELCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Methylphenidate

    Therapeutic Area : Psychiatry/Psychology

    Study Phase : Approved

    Sponsor : Aytu BioScience

    Deal Size : $44.9 million

    Deal Type : Merger

    DEALS_DEV arrow-down

    Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement

    Details : Aytu adds Neos' established, multi-brand ADHD portfolio which includes Adzenys XR-ODT and Cotempla XR-ODT, enhancing Aytu's footprint in pediatrics and expanding its presence in adjacent specialty care segments.

    Product Name : Cotempla XR-ODT

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    December 10, 2020

    Lead Product(s) : Methylphenidate

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Approved

    Sponsor : Aytu BioScience

    Deal Size : $44.9 million

    Deal Type : Merger

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Moksha8 Pharmaceuticals

    U.S.A arrow
    ELCC
    Not Confirmed

    Moksha8 Pharmaceuticals

    U.S.A arrow
    ELCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Methylphenidate

    Therapeutic Area : Psychiatry/Psychology

    Study Phase : Approved

    Sponsor : Johnson & Johnson Innovative Medicine

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Moksha8 Pharmaceuticals Announces Strategic Partnership with Janssen for Selected CNS Portfolio in Mexico

    Details : The strong and diverse portfolio includes: CONCERTA®, HALDOL®, HALDOL® DECANOAS, REMINYL®, SIBELIUM®, RISPERDAL®, RISPERDAL CONSTA® and TOPAMAX®.

    Product Name : Concerta

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    September 29, 2020

    Lead Product(s) : Methylphenidate

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Approved

    Sponsor : Johnson & Johnson Innovative Medicine

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth